Two Sigma Advisers
EPZM

Two Sigma Advisers’s Epizyme, Inc EPZM Stock Holding History

Two Sigma Advisers’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-379,300
Closed -$436K – 2975
2022
Q1 		$436K Buy
379,300
+63,900
+20% +$104K ﹤0.01% 2052
2021
Q4 		$789K Buy
+315,400
New +$1.24M ﹤0.01% 1688
2021
Q2 		– Sell
-20,800
Closed -$181K – 2785
2021
Q1 		$181K Buy
20,800
+1,400
+7% +$14.5K ﹤0.01% 2370
2020
Q4 		$211K Sell
19,400
-152,800
-89% -$1.89M ﹤0.01% 2153
2020
Q3 		$2.05M Buy
172,200
+99,100
+136% +$1.33M 0.01% 1151
2020
Q2 		$1.17M Buy
+73,100
New +$1.28M ﹤0.01% 1501
2019
Q1 		– Sell
-12,400
Closed -$76K – 2490
2018
Q4 		$76K Buy
+12,400
New +$94.7K ﹤0.01% 2244

Other funds holding EPZM

RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers's EPZM Position: Q2 2022 in Review

Two Sigma Advisers sold out of Epizyme, Inc (EPZM) in Q2 2022, closing a stake of 379,300 shares — an estimated $436K sold.

Two Sigma Advisers first reported a position in EPZM in Q4 2018 and held it in 7 quarters. The position peaked at $2.05M in Q3 2020. 93 funds tracked by Wall St. Rank hold EPZM as of Q2 2022.

  • Two Sigma Advisers reported no remaining Epizyme, Inc position as of Q2 2022 after selling out during the quarter.
  • Two Sigma Advisers sold 379,300 Epizyme, Inc shares in Q2 2022, an estimated $436K.
  • Two Sigma Advisers first reported a position in Epizyme, Inc in Q4 2018 and held it in 7 quarters.
  • Two Sigma Advisers's Epizyme, Inc position peaked at $2.05M in Q3 2020.
  • 93 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2022.

Based on Two Sigma Advisers's 13F filing for Q2 2022, filed 15 Aug 2022.